1 BTC
=
- USD
Cybin Inc.
As of May 30, 2026 at 24:05 UTC
Chart
About Cybin Inc.
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The Company is a clinical-stage neuropsychiatric company focused on advancing therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions. The Company is developing technologies and delivery systems aimed at improving the pharmacokinetics of its proprietary molecules while retaining the therapeutic benefit. These new molecules and delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.
Market Statistics
Trading Metrics
How to Buy CYBN
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy CYBN
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesPsychedelic Science 2025, a leading conference on psychedelic research, policy, and thought leadership, announces its initial lineup of speakers, including former U.S. Senator Kyrsten Sinema, former Ohio Representative Tim Ryan, and other prominent researchers, policymakers, and advocates.
The 5-HT2 agonist pipeline is robust, with over 20 pharmaceutical companies actively developing 22+ pipeline drugs. Advancements in precision medicine and personalized approaches are driving the market, enabling selective targeting of receptor subtypes and improving safety and efficacy.
Water Tower Research has published an Initiation of Coverage Report on Cybin, Inc., a leader in novel neuropsychiatry therapeutics. Cybin's primary focus is on two lead pipeline candidates, CYB003 for major depressive disorder and CYB004 for generalized anxiety disorder, which have shown promising results in clinical trials.
Cybin Inc. (CYBN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Cybin Inc. (CYBN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.